WPWietse In Het Panhuis

Wietse In Het Panhuis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wietse In Het Panhuis has a total of 160 co-authors. Here are the top co-authors by number of shared publications:

  • Patrick C. N. Rensen

    Leiden University Medical Center

    7 shared publications
  • Sander Kooijman

    Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands

    7 shared publications
  • Milena Schönke

    Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands

    5 shared publications
  • Salwa Afkir

    Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, Netherlands

    5 shared publications
  • Amanda C. M. Pronk

    Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, Netherlands

    4 shared publications
  • Milena Schönke

    Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands

    4 shared publications

Latest Publications

  • Open Access

    Increasing plasma bile salt levels with Bulevirtide alleviates DSS-induced colitis and LPS-induced inflammation

    by Thuc-Anh Nguyen, Reinout Lp Roscam Abbing, Pim J Koelink, Joost M Lambooij, Wietse In Het Panhuis, Dirk R de Waart, Isabelle Bolt, Suzanne Duijst, Esther Vogels, Ricky Siebeler, et al.

    Background & Aims: Bulevirtide, a viral entry inhibitor used to treat chronic hepatitis delta virus (HDV) infection, targets the hepatic bile salt transporter Na + -Taurocholate Co-transporting Polypeptide (NTCP). As Bulevirtide displays preclinical potential to mitigate cholestatic liver injury, NTCP inhibition is currently explored as treatment for primary sclerosing cholangitis (PSC), a condition frequently associated with colitis. Here, we investigated the immunomodulatory effects of Bulevirtide in lipopolysaccharide (LPS)-induced inflammation and dextran sodium sulfate (DSS)-induced colitis in mice. Methods: The immunomodulatory properties of the bile salt taurochenodeoxycholic acid (TCDC) were investigated in LPS-challenged mouse bone marrow-derived macrophages (BMDM) and human BLaER1 macrophages. The therapeutic efficacy of Bulevirtide against LPS-induced inflammation and DSS-induced colitis was evaluated in Slco1a/1b -/- FVB and C57BL/6J mice, which recapitulate human bile salt dynamics. Results: In BMDMs, TCDC reduced pro-inflammatory tumor necrosis factor alpha (TNF), increased anti-inflammatory interleukin (IL)-10, and suppressed inflammasome activation, as evidenced by reduced IL-1β, IL-18 and cleaved-IL-1β levels. Consistently, TCDC also reduced TNF and IL1B expression in human BLaER1 macrophages. In both FVB and C57BL/6J Slco1a/1b -/- mice , Bulevirtide increased plasma bile salt levels at least 30-fold. This systemic elevation of bile salts reduced plasma TNF and increased IL-10 in LPS-treated mice. Moreover, Bulevirtide attenuated DSS-induced colitis, evidenced by reduced disease scores and reduced intestinal Tnf expression. Conclusion: These findings highlight the anti-inflammatory effects of bile salts in preclinical models of colitis and support NTCP inhibition as a future therapeutic strategy to ameliorate both cholestasis and colitis in PSC. Graphical Synopsis: Inhibition of the Na + -Taurocholate Co-transporting Polypeptide using Bulevirtide induces systemic bile salt elevation and mitigates acute inflammation and colitis in mice. These findings support clinical evaluation of Bulevirtide in primary sclerosing cholangitis with protective effects against cholestasis and colitis.

  • Open Access

    The designer cytokine IC7Fc attenuates atherosclerosis development by targeting hyperlipidemia in mice

    by Wietse In Het Panhuis, Ellen Thiemann, Daisy M. A. H. van Dijk, Bibian Been, Kelsey E. Jarrett, Amber Meurs, Sander Kooijman, Milaine V. Hovingh, Melanie Modder, Bram W. van Os, et al.

    The chimeric cytokine IC7Fc conveys the metabolic signaling properties of the glycoprotein 130 receptor cytokines interleukin-6 and ciliary neurotrophic factor via membrane-bound signaling. IC7Fc was previously shown to slow the progression of type 2 diabetes mellitus, and here, we demonstrate its effect on atherosclerotic development. In APOE*3-Leiden.CETP mice, an atherosclerosis-prone model with a humanized lipoprotein metabolism, IC7Fc markedly lowered plasma triglyceride and total cholesterol levels. This was mechanistically explained by an inhibition of de novo lipogenesis in the liver, increased synthesis of bile acids from cholesterol, and down-regulated apolipoprotein B synthesis, which resulted in decreased cholesterol secretion in very low–density lipoprotein particles. As a consequence, IC7Fc treatment considerably reduced atherosclerotic lesion formation and vascular inflammation compared with current antihyperlipidemic therapy. In conclusion, IC7Fc is a promising pharmacological treatment for cardiometabolic diseases targeting hyperlipidemia and inflammation.


  • Open Access

    ATP8B1 Deficiency Causes Phosphodiesterase 4‐Mediated Glucagon Resistance and Impaired Gluconeogenesis in Mouse and Human Liver

    by Jung‐Chin Chang, Wietse In Het Panhuis, Shu‐Hao Hsu, Suzanne Duijst, Kam S. Ho‐Mok, Jolie F. van der Heiden, Zhixiong Ying, Joris I. Erdmann, Georg F. Vogel, Norman Junge, et al.

    Background and Aims: Deficiency of the phospholipid transporter ATP8B1 causes infantile‐onset progressive familial intrahepatic cholestasis type I (PFIC1). Pre‐transplant PFIC1 patients often present with mild dyslipidaemia. This raises the possibility that PFIC1 patients, besides cholestasis, may also experience defects in glucose and lipid metabolism. In this study, we aimed to investigate the role of ATP8B1 in hepatic glucose and lipid metabolism using the Atp8b1 G308V/G308V mutant mouse, a pre‐clinical model of PFIC1. Methods: Atp8b1 G308V/G308V and wild‐type mice on normal chow were examined. Hepatic glucose metabolism was evaluated by oral glucose tolerance testing, quantification of fasting plasma glucose, insulin and lipids. Mechanistic studies were conducted in primary mouse hepatocytes (PMHs) and HepG2 cells overexpressing glucagon receptor (HepG2‐GCGR). The findings in the mouse model were validated in pre‐transplant livers from PFIC1 patients. Results: Atp8b1 G308V/G308V mice showed decreased levels of fasting blood glucose, triglycerides and insulin, indicating normal insulin sensitivity and impaired hepatic glucagon response. PMHs from Atp8b1 G308V/G308V mice exhibited reduced glucagon‐dependent cAMP levels and signalling and had increased expression of Pde4 isoforms. Rolipram‐mediated PDE4 inhibition restored glucagon signalling. ATP8B1 knockdown HepG2‐GCGR cells also showed increased PDE4D expression and impaired glucagon signalling. Liver tissue from PFIC1 patients exhibited elevated PDE4D and reduced p‐CREB levels and very low glycogen content. Conclusions: ATP8B1 deficiency causes upregulation of PDE4D in the liver of Atp8b1 G308V/G308V mice and PFIC1 patients. PDE4D‐mediated glucagon resistance impairs gluconeogenesis and stimulates compensatory glycogenolysis in Atp8b1 G308V/G308V mice and PFIC1 patients. Our study reveals novel metabolic insights of ATP8B1 deficiency in PFIC1 patients.


  • Open Access

    NK2R control of energy expenditure and feeding to treat metabolic diseases

    by Frederike Sass, Tao Ma, Jeppe H. Ekberg, Melissa Kirigiti, Mario G. Ureña, Lucile Dollet, Jenny M. Brown, Astrid L. Basse, Warren T. Yacawych, Hayley B. Burm, et al.

    The combination of decreasing food intake and increasing energy expenditure represents a powerful strategy for counteracting cardiometabolic diseases such as obesity and type 2 diabetes1. Yet current pharmacological approaches require conjugation of multiple receptor agonists to achieve both effects2,3,4, and so far, no safe energy-expending option has reached the clinic. Here we show that activation of neurokinin 2 receptor (NK2R) is sufficient to suppress appetite centrally and increase energy expenditure peripherally. We focused on NK2R after revealing its genetic links to obesity and glucose control. However, therapeutically exploiting NK2R signalling has previously been unattainable because its endogenous ligand, neurokinin A, is short-lived and lacks receptor specificity5,6. Therefore, we developed selective, long-acting NK2R agonists with potential for once-weekly administration in humans. In mice, these agonists elicit weight loss by inducing energy expenditure and non-aversive appetite suppression that circumvents canonical leptin signalling. Additionally, a hyperinsulinaemic–euglycaemic clamp reveals that NK2R agonism acutely enhances insulin sensitization. In diabetic, obese macaques, NK2R activation significantly decreases body weight, blood glucose, triglycerides and cholesterol, and ameliorates insulin resistance. These findings identify a single receptor target that leverages both energy-expending and appetite-suppressing programmes to improve energy homeostasis and reverse cardiometabolic dysfunction across species.


  • Open Access

    Getting in the zone: Metabolite transport across liver zones

    by Stan F. J. van de Graaf, Coen C. Paulusma, Wietse In Het Panhuis

    The liver has many functions including the regulation of nutrient and metabolite levels in the systemic circulation through efficient transport into and out of hepatocytes. To sustain these functions, hepatocytes display large functional heterogeneity. This heterogeneity is reflected by zonation of metabolic processes that take place in different zones of the liver lobule, where nutrient‐rich blood enters the liver in the periportal zone and flows through the mid‐zone prior to drainage by a central vein in the pericentral zone. Metabolite transport plays a pivotal role in the division of labor across liver zones, being either transport into the hepatocyte or transport between hepatocytes through the blood. Signaling pathways that regulate zonation, such as Wnt/β‐catenin, have been shown to play a causal role in the development of metabolic dysfunction‐associated steatohepatitis (MASH) progression, but the (patho)physiological regulation of metabolite transport remains enigmatic. Despite the practical challenges to separately study individual liver zones, technological advancements in the recent years have greatly improved insight in spatially divided metabolite transport. This review summarizes the theories behind the regulation of zonation, diurnal rhythms and their effect on metabolic zonation, contemporary techniques used to study zonation and current technological challenges, and discusses the current view on spatial and temporal metabolite transport.


  • Open Access

    Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice

    by Melanie Modder, Wietse In Het Panhuis, Mohan Li, Salwa Afkir, Alexandra L Dorn, Amanda C M Pronk, Trea C M Streefland, Reshma A Lalai, Stefan Pierrou, Stefan K Nilsson, et al.

    Angiopoietin-like 3 (ANGPTL3) and 4 (ANGPTL4) inhibit lipoprotein lipase to regulate tissue fatty acid uptake from triglyceride-rich lipoproteins such as VLDL. While pharmacological inhibition of ANGPTL3 is being evaluated as lipid-lowering strategy, systemic ANGPTL4 inhibition is not pursued due to adverse effects. This study aimed to compare the therapeutic potential of liver-specific Angptl3 and Angptl4 silencing to attenuate hyperlipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice, a well-established humanized model for lipoprotein metabolism. Mice were subcutaneously injected twice-weekly with saline or liver-targeted antisense oligonucleotides against Angptl3, Angptl4, both, or a scrambled oligonucleotide. Plasma lipid levels, VLDL clearance and hepatic VLDL production were determined, and atherosclerosis development was assessed. For toxicological evaluation, cynomolgus monkeys were treated with three dosages of liver-targeted ANGPTL4-silencing oligonucleotides. Liver-targeted Angptl4 silencing reduced plasma triglycerides (-48%) and total cholesterol (-56%), explained by higher VLDL-derived fatty acid uptake by brown adipose tissue and lower VLDL production by the liver. Accordingly, Angptl4 silencing reduced atherosclerotic lesion size (-86%) and improved lesion stability. Hepatic Angptl3 silencing similarly attenuated hyperlipidemia and atherosclerosis development. While Angptl3 and Angptl4 silencing lowered plasma triglycerides in the refed and fasted state, respectively, combined Angptl3/4 silencing lowered plasma triglycerides independent of nutritional state. In cynomolgus monkeys, anti-ANGPTL4 ASO treatment was well tolerated without adverse effects. Liver-targeted Angptl4 silencing potently attenuates hyperlipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice, and liver-targeted ANGPTL4 silencing is well-tolerated in non-human primates. These data warrant further clinical development of liver-targeted ANGPTL4 silencing.


  • Open Access

    Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1 Ldlr mice

    by Begoña Porteiro, Reinout L.P. Roscam Abbing, Wietse In Het Panhuis, Dirk R. de Waart, Suzanne Duijst, Isabelle Bolt, Esther W. Vogels, Johannes H.M. Levels, Laura A. Bosmans, Winnie G. Vos, et al.


  • Open Access

    Angiopoietin-like 4 dictates the day-night rhythm of metabolic brown adipose tissue activity

    by Robin Van Eenige, Wietse In Het Panhuis, Milena Schönke, Céline Jouffe, Thomas Devilee, Ricky Siebeler, Trea Streefland, Hetty Sips, Amanda Pronk, Ruben Vorderman, et al.

    View, download and discuss this poster on Peeref: Angiopoietin-like 4 dictates the day-night rhythm of metabolic brown adipose tissue activity. Peeref makes academic exchange simple.

  • Open Access

    Time-restricted feeding attenuates hypercholesterolaemia and atherosclerosis development during circadian disturbance in APOE∗3-Leiden.CETP mice

    by Wietse In Het Panhuis, Milena Schönke, Melanie Modder, Hannah E. Tom, Reshma A. Lalai, Amanda C.M. Pronk, Trea C.M. Streefland, Linda W.M. van Kerkhof, Martijn E.T. Dollé, Marie A.C. Depuydt, et al.


  • Open Access

    Circadian disruption impairs glucose homeostasis in male but not in female mice and is dependent on gonadal sex hormones

    by Wietse In Het Panhuis, Milena Schönke, Ricky Siebeler, Dorien Banen, Amanda C. M. Pronk, Trea C. M. Streefland, Salwa Afkir, Hetty C. M. Sips, Jan Kroon, Patrick C. N. Rensen, et al.

    Circadian disruption (CD) is the consequence of a mismatch between endogenous circadian rhythms and behavior, and frequently occurs in shift workers. CD has often been linked to impairment of glucose and lipid homeostasis. It is, however, unknown if these effects are sex dependent. Here, we subjected male and female C57BL/6J mice to 6‐h light phase advancements every 3 days to induce CD and assessed glucose and lipid homeostasis. Within this model, we studied the involvement of gonadal sex hormones by injecting mice with gonadotropin‐releasing hormone‐antagonist degarelix. We demonstrate that CD has sex‐specific effects on glucose homeostasis, as CD elevated fasting insulin levels in male mice while increasing fasting glucose levels in female mice, which appeared to be independent of behavior, food intake, and energy expenditure. Absence of gonadal sex hormones lowered plasma insulin levels in male mice subjected to CD while it delayed glucose clearance in female mice subjected to CD. CD elevated plasma triglyceride (TG) levels and delayed plasma clearance of TG‐rich lipoproteins in both sexes, coinciding with reduced TG‐derived FA uptake by adipose tissues. Absence of gonadal sex hormones did not notably alter the effects of CD on lipid metabolism. We conclude that CD causes sex‐dependent effects on glucose metabolism, as aggravated by male gonadal sex hormones and partly rescued by female gonadal sex hormones. Future studies on CD should consider the inclusion of both sexes, which may eventually contribute to personalized advice for shift workers.